DocStoX is a free AI-powered research platform for Indian equity markets, covering 6,800+ NSE & BSE stocks with prices, fundamentals, 326 financial ratios, shareholding, FII/DII flows, F&O, IPOs, a visual screener and AI stock scoring.

Yes. DocStoX has a free tier covering stock research, the screener, FII/DII data and educational guides, plus a free MCP API tier (50 tool calls/day) for AI assistants. A Pro plan adds higher limits and advanced features.

What data does DocStoX cover?

Every NSE & BSE listed stock (6,800+ instruments): EOD and intraday prices, income statement / balance sheet / cash flow, 326 ratios, quarterly shareholding, promoter pledge, mutual-fund holdings, FII/DII flows, F&O and option-chain data, analyst forecasts, IPOs, corporate actions and news.

Can AI assistants like ChatGPT or Claude use DocStoX data?

Yes. DocStoX runs a public Model Context Protocol (MCP) server at https://mcp.docstox.com/mcp with 39 tools, so Claude, ChatGPT, Cursor and other MCP clients can pull Indian market data directly. Setup and a free key are at https://docstox.com/mcp.

What is the ZYDUS LIFESCIENCES LTD (ZYDUSLIFE) share price today?

ZYDUS LIFESCIENCES LTD (ZYDUSLIFE) is trading at ₹1,143.7 on the NSE, down 0.88% on the day. Source: DocStoX.

What is the PE ratio of ZYDUS LIFESCIENCES LTD?

ZYDUS LIFESCIENCES LTD has a price-to-earnings (PE) ratio of 22.8 in the Healthcare sector.

What is the market capitalisation of ZYDUS LIFESCIENCES LTD?

ZYDUS LIFESCIENCES LTD has a market capitalisation of approximately ₹1,15,087 crore.

ZYDUS LIFESCIENCES LTD

F&O

ZYDUSLIFE·NSE·Healthcare

₹1,143.70▼ -10.20 (-0.88%)

Healthcare · Pharmaceuticals

High-quality returns — 21% on equity

NIFTY NEXT 50NIFTY 100NIFTY 200

Day₹1134.80

₹1156.70

52W₹836

₹118289%

Open

₹1150.00

High

₹1156.70

Low

₹1134.80

Prev Close

₹1153.90

Volume

12.41L

VWAP

₹1141.34

Snapshot

Key fundamentals

Market Cap

₹1.15L Cr

P/E Ratio

22.83Fair

P/B Ratio

4.09

EPS

₹50.09

Book Value

₹269.00

ROE

21.20%Strong

ROCE

21.00%Efficient

Dividend Yield

0.09%

Debt / Equity

0.46Moderate

Face Value

₹1.00

52W High

₹1181.50

52W Low

₹835.50

Sector

Healthcare

Industry

Pharmaceuticals

Avoid

Narrow moatMedium uncertainty

Fair value estimate

₹426

▼ 62.8%downside

Trading at ₹1,144 — 63% above our estimate

BearFair valueBull

₹362₹426₹551

/100

Business quality — Solid

Growth 83Profitability 87Efficiency 33Valuation 72

Plain English

Our view

High-quality returns — 21% on equity
Low debt relative to equity
Fundamental red flags (Piotroski 2/9)

Strengths

Low debt relative to equity
Strong returns on equity (21%)
Capital is working hard (ROCE 21%)
Revenue compounding 16% over 3 years

Risks

Fundamental red flags (Piotroski 2/9)

How we got there

Fair value methods

Residual income

21% ROE fading to 13% over ~10 yrs, on ₹269 book

₹391

Relative P/E

Needs ≥3 peers with P/E

—

Graham floor

Conservative floor: √(22.5 × EPS × book value/share)

₹551

Analyst target

No analyst coverage

—

Blended fair value₹426

What the numbers say

Investment thesis

Bull case

Low debt relative to equity
Strong returns on equity (21%)
Capital is working hard (ROCE 21%)
Revenue compounding 16% over 3 years
Profit growing 35% a year
Promoters hold a controlling stake

Bear case

Fundamental red flags (Piotroski 2/9)

Free — see our deterministic Fair Value range, business quality score, and the full bull/bear case for this stock.

Snapshot

Key statistics

P/E

22.8Fair

Below 15× is value territory; above 35× prices in strong growth

ROE

21.2%Strong

Above 15% is considered healthy for Indian equities

ROCE

21.0%Efficient

Above 18% means capital is working hard

Debt/Eq

0.46Moderate

Below 0.5 is comfortable; above 1.5 strains the balance sheet

Mkt Cap

₹1.15L Cr

P/B

4.09

EPS

₹50.09

Div Yield

0.09%

What changed

Recent changes

No notable changes to report.

What matters

News impact

Overview

Valuation

Reasonable

P/E 22.8×

Growth

Strong

+16% rev CAGR

Profitability

Excellent

21.2% ROE

Financial health

Comfortable

D/E 0.46

Momentum

N/A

No technicals

Today

Trading activity

Delivery %54.8%

Turnover₹14158.56L Cr

Trades38,104

VWAP₹1141.34

Face value₹1.00

Market depth

Market depth available during market hours

Snapshot

Technical signals

Compounded annual growth

Growth (CAGR)

Revenue

+16.4%

+12.4%

10Y

+11.2%

Profit

+34.8%

+18.6%

10Y

+10.1%

EPS

+37.3%

+19.2%

10Y

+10.2%

Profile

Pros

Company has delivered good profit growth of 18.8% CAGR over last 5 years

Forecast

News

Peers

Financials

Growth

Shareholding

Ownership

Ownership breakdown

Quarter ending 30 Jun 2026

Ownership was broadly stable versus the previous quarter. The QoQ column shows each group's change versus the prior quarter.

75%

Promoter

Promoters

75.0%+0.01

Public

5.5%-0.08

FII / FPI

6.9%-0.06

DII

11.2%-0.01

Others

1.4%

Total shareholders

4,03,889-14,425 QoQ

Quarterly trend

Ownership over time

Q1 FY27

Promoter75.01%

FII6.89%

DII11.19%

Public5.46%

Others1.45%

Corporate Actions

Bulk & Block Deals

Filings

MF Holdings

Technicals

FAQs

Quick reference

Frequently asked questions

F&O